ArticleCell2021
Translocated microbiome composition determines immunological outcome in treated HIV infection.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 78 citations in OpenAlex.
- Benchmarking methods for extracting microbial signal from host-dominated metatranscriptomes.Briefings in bioinformatics · 2026Article
- Microbial product translocation and mortality in adults hospitalised with HIV-associated tuberculosis: a prospective observational cohort study.Research square · 2026Article
- Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.Nature microbiology · 2026Article
- Cytokine Concentrations in Seminal Plasma and Blood in HIV Infection: Differential Modulation by Antiretroviral Therapy and Association with HIV RNA Levels and CD4International journal of general medicine · 2026Article
- Persistent CD8Frontiers in immunology · 2026Article
- Immune cells harbor their own microbiome-derived metabolome: a new layer of immunometabolic regulation.Frontiers in immunology · 2026Review
- Decreased intestinal abundance ofAnnals of medicine · 2025Article
- Short-term antiretroviral therapy may not correct the dysregulations of plasma virome and cytokines induced by HIV-1 infection.Virulence · 2025Article
- Wastewater Measures of SARS-CoV-2 Accurately Predict Frequency of Symptomatic Infections in the Community.The Journal of infectious diseases · 2025Observational
- Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.Blood · 2025Article
- Gut microbiota-associated non-cholesterol sterol dysregulation modulates immune reconstitution during antiretroviral therapy in people living with HIV.Microbiology spectrum · 2025Article
- NK cell activation and CD4+ T cell α4β7 expression are associated with susceptibility to HIV-1.The Journal of clinical investigation · 2025Article
- Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Patterns of immune recovery in people living with HIV who initiated antiretroviral therapy as late presenters.BMC infectious diseases · 2025Article
- Tripartite interplay: immune reconstitution dynamics in AIDS, gut microbiota, and Helicobacter pylori infection: current advances and therapeutic prospects.Gut pathogens · 2025Article
- Disrupted microbial cross-feeding and altered L-phenylalanine consumption in people living with HIV.Briefings in bioinformatics · 2025Article
- Peripheral blood microbiome signature and Mycobacterium tuberculosis-derived rsRNA as diagnostic biomarkers for tuberculosis in human.Journal of translational medicine · 2025Article
- Metagenomic analysis of blood microbiota alterations: insights into HIV progression and immune restoration.Frontiers in cellular and infection microbiology · 2025Article
- Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract.Pathogens & immunity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 4 countries.
Krystelle Nganou-MakamdopHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Institute of Clinical and Molecular Virology, University Hospital Erlangen, 91054 Erlangen, Germany.
Aarthi TallaDepartment of Pathology, Case Western Reserve University, Cleveland, OH 10900, USA; Allen Institute for Immunology, Seattle, WA 98109, USA.
Ashish Arunkumar SharmaDepartment of Pathology, Case Western Reserve University, Cleveland, OH 10900, USA; Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Sam DarkoHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Amy RansierHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Farida LabouneHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jeffrey G ChipmanDepartment of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Gregory J BeilmanDepartment of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Torfi HoskuldssonDepartment of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Slim FouratiDepartment of Pathology, Case Western Reserve University, Cleveland, OH 10900, USA; Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Thomas E SchmidtDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Sahaana ArumugamHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Noemia S LimaHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Damee MoonHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Samuel CallistoDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Jordan SchoephoersterDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Jeffery TomalkaDepartment of Pathology, Case Western Reserve University, Cleveland, OH 10900, USA; Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Peter MugyenyiJoint Clinical Research Center, Kampala, Uganda.
Francis SsaliJoint Clinical Research Center, Kampala, Uganda.
Proscovia MulomaJoint Clinical Research Center, Kampala, Uganda.
Patrick SsengendoJoint Clinical Research Center, Kampala, Uganda.
Ana R LedaDepartment of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL 33124, USA.
Ryan K CheuDepartment of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL 33124, USA.
Jacob K FlynnBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, MD 20892, USA.
Antigoni MorouResearch Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada; Université de Montréal, Montreal, QC H3C 3J7, Canada; Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Elsa Brunet-RatnasinghamResearch Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada; Université de Montréal, Montreal, QC H3C 3J7, Canada.
Benigno RodriguezCase Western Reserve University School of Medicine, Cleveland, OH 10900, USA.
Michael M LedermanCase Western Reserve University School of Medicine, Cleveland, OH 10900, USA.
Daniel E KaufmannResearch Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada; Université de Montréal, Montreal, QC H3C 3J7, Canada.
Nichole R KlattDepartment of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL 33124, USA.
Cissy KityoJoint Clinical Research Center, Kampala, Uganda.
Jason M BrenchleyBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, MD 20892, USA.
Timothy W SchackerDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: schacker@umn.edu.
Rafick P SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH 10900, USA; Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: rafick.sekaly@emory.edu.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: ddouek@mail.nih.gov.
National Institutes of Health · USUniversity of Minnesota · USJoint Clinical Research Centre · UGEmory University · USUniversity of Miami · USCentre Hospitalier de l’Université de Montréal · CANational Institute of Allergy and Infectious Diseases · USUniversity School · USAllen Institute for Immunology · USRoche Pharma AG (Germany) · DE
Funding
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0MHost Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9MThe Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9MVirological Measurements of Cryptic ReplicationP01AI074340 · NIAID · UNIVERSITY OF MINNESOTA · PI SCHACKER, TIMOTHY W · 2008 to 2012
$12.1MT Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4MHarnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIVR37AI141258 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2018 to 2026
$7.8MThe HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5MInnate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8MInflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9MAn unbiased OMICs approach to identify mechanisms of Cocaine regulation of the HIV reservoir.R01DA043263 · NIDA · EMORY UNIVERSITY · PI SEKALY, RAFICK PIERRE · 2016 to 2020
$5.8MThe Lymphoid Tissue Pharmacology of Antiretroviral DrugsR01AI124965 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FLETCHER, COURTNEY V · 2016 to 2020
$3.7MOMICs to define impact of cocaine on immunity and HIV persistence in treated HIV infectionR01DA042712 · NIDA · EMORY UNIVERSITY · PI SEKALY, RAFICK PIERRE · 2016 to 2020
$3.5MCanadian Institute for Health Research CIHR-168901NHLBI NIH HHS R01 HL092565NIAID NIH HHS P01 AI074340NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI124965NIAID NIH HHS R37 AI141258NIAID NIH HHS U01 AI141981NIDA NIH HHS R01 DA042712NIDA NIH HHS R01 DA043263NIDDK NIH HHS R01 DK112254
Abstract
The impact of the microbiome on HIV disease is widely acknowledged although the mechanisms downstream of fluctuations in microbial composition remain speculative. We detected rapid, dynamic changes in translocated microbial constituents during two years after cART initiation. An unbiased systems biology approach revealed two distinct pathways driven by changes in the abundance ratio of Serratia to other bacterial genera. Increased CD4 T cell numbers over the first year were associated with high Serratia abundance, pro-inflammatory innate cytokines, and metabolites that drive Th17 gene expression signatures and restoration of mucosal integrity. Subsequently, decreased Serratia abundance and downregulation of innate cytokines allowed re-establishment of systemic T cell homeostasis promoting restoration of Th1 and Th2 gene expression signatures. Analyses of three other geographically distinct cohorts of treated HIV infection established a more generalized principle that changes in diversity and composition of translocated microbial species influence systemic inflammation and consequently CD4 T cell recovery.
Indexed as
Gastrointestinal MicrobiomeAntiretroviral Therapy, Highly ActiveBiodiversityCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChemokinesCohort StudiesGlycolysisHIV InfectionsHumansInflammationMitochondriaMonocytesNucleic AcidsPrincipal Component AnalysisSerratiaChemokinesNucleic Acidsantiretroviral therapyHIVinflammationmicrobiomesystems biology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.